RELATING TO ACCESS TO TREATMENT FOR TERMINALLY ILL PATIENTS.
Summary
Permits manufacturers of investigational drugs or biological products beginning on January 1, 2018 to make these drugs and products available to terminally ill patients under certain conditions, including while pending participation in the federal expanded access program.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jan 2017
Committee Review
Floor Vote
Governor
Introduced Jan 25, 2017
Last action Jan 17, 2018
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
5
Key actions
0
Committee
2
Jan 17, 2018
Senate · Referred to committee
Re-Referred to CPH, JDC.
Jan 27, 2017
Senate · Referred to committee
Referred to CPH, JDL.
Jan 25, 2017
Senate · Introduced
Introduced.
3 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
BH
Breene Harimoto
DDemocratic
P
Karl Rhoads
DDemocratic
P
Stanley Chang
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 1110
Scope: HI
Hi! I can help you understand SB 1110. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline